BAX as the mediator of C-MYC sensitizes acute lymphoblastic leukemia to TLR9 agonists.

ABSTRACT:

Background

The prognosis of B-cell acute lymphoblastic leukemia (B-ALL) has improved significantly with current first-line therapy, although the recurrence of B-ALL is still a problem. Toll-like receptor 9 (TLR9) agonists have shown good safety and efficiency as immune adjuvants. Apart from their immune regulatory effect, the direct effect of TLR9 agonists on cancer cells with TLR9 expression cannot be ignored. However, the direct effect of TLR9 agonists on B-ALL remains unknown.

Methods

We discussed the relationship between TLR9 expression and the clinical characteristics of B-ALL and explored whether CpG 685 exerts direct apoptotic effect on B-ALL without inhibiting normal B-cell function. By using western blot, co-immunoprecipitation, immunofluorescence co-localization, a

SUBMITTER: Bai L 

PROVIDER: S-EPMC9921080 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature